Press Releases May 7, 2026 07:30 AM

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

Repligen to Present at Bank of America Securities 2026 Global Healthcare Conference in May

By Hana Yamamoto RGEN

Repligen Corporation, a leader in bioprocessing technologies for biopharmaceutical manufacturing, announced its participation in the Bank of America Securities 2026 Global Healthcare Conference with CFO Jason Garland leading a discussion. The event will be webcast live and available for replay, highlighting the company's ongoing engagement with investors and industry experts.

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
RGEN

Key Points

  • Repligen Corporation is participating in a major healthcare conference, showcasing its leadership in bioprocessing technology.
  • The company focuses on enabling efficiencies in biological drug manufacturing, serving biopharmaceutical developers and CDMOs.
  • Live webcast of the presentation allows broad access for investors and stakeholders to learn about Repligen's strategic direction.

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on May 12 at 10:00am PT.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
[email protected]


Risks

  • Market response to the presentation content is uncertain and may not impact stock price significantly.
  • Competition in bioprocessing technology could affect Repligen's future growth prospects.
  • Global manufacturing footprint exposes the company to geopolitical or operational risks across multiple countries.

More from Press Releases

Fervo Energy Announces Pricing of its Upsized Initial Public Offering May 12, 2026 Titan Mining Delivers 22% Revenue Growth and Expands U.S. Critical Minerals Platform with Graphite Production May 12, 2026 Anteris Announces Results for the First Quarter of 2026 May 12, 2026 Copa Holdings Announces Monthly Traffic Statistics for April 2026 May 12, 2026 Aeluma to Participate in Upcoming Investor Conferences May 12, 2026